SAPIEN 3 Ultra from Edwards Lifesciences Corp. - lower-profile TAVI and refined delivery
23.06.2026 - 07:38:23 | ad-hoc-news.de
Reviewed: ad hoc news New Release & Launch desk. Edited and checked on 2026-06-23, 07:35. Details in the imprint.
The SAPIEN 3 Ultra sits on a clean steel tray, its cobalt-chromium frame catching the theatre light while the delivery catheter feels surprisingly smooth in a gloved hand. For interventional cardiologist Martin Leon, this valve has turned high-risk surgery patients into quiet cath-lab cases.
What SAPIEN 3 Ultra changes
The SAPIEN 3 Ultra is Edwards Lifesciences' latest transcatheter aortic valve replacement system for severe, symptomatic aortic stenosis in patients at increased risk for open-heart surgery. According to the company, it builds on the SAPIEN 3 platform with an enhanced outer skirt to further reduce paravalvular leak.Official SAPIEN 3 Ultra product information
The valve is delivered via the Commander delivery system and is available in multiple diameters to match different annulus sizes, with balloon-expandable deployment providing the sharp positioning control many operators prefer. Edwards highlights that the system is intended for femoral access routes with a smaller overall profile compared with earlier SAPIEN iterations.
How it feels in the cath lab
In practice, operators describe the Ultra delivery catheter as more tactile and forgiving when navigating tortuous iliac arteries, with the hydrophilic coating giving a smooth gliding sensation over the guidewire during advancement into the aortic root. The lower-profile sheath means nurses see less groin bruising and smaller puncture sites when they pull the lines post-procedure.Clinical experience report in JACC: Cardiovascular Interventions
For patients, the most convincing difference is not something they see, but what they avoid: no sternotomy scar, no days of ventilator time, and often discharge after one or two nights. Many report the raw sensation of chest pressure easing within hours as the new valve starts to carry full cardiac output.
Background on Edwards Lifesciences shares
The SAPIEN valve line is a core growth driver for Edwards Lifesciences, and new iterations like the SAPIEN 3 Ultra often feature prominently in market analysis on the group.
Clinical positioning and evidence
Edwards Lifesciences secured CE mark for SAPIEN 3 Ultra in Europe and regulatory clearance in key markets including the US, extending the indication from high- and intermediate-risk patients to certain low-risk cohorts based on accumulating TAVI data.Edwards Lifesciences CE mark announcement
Randomised trials and large registries have shown balloon-expandable TAVI systems like SAPIEN reduce all-cause mortality and heart failure hospitalisations compared with standard medical therapy in inoperable patients, and are non-inferior or better than surgical valve replacement in many risk groups. This evidence base underpins guideline recommendations from major cardiology societies.
Pricing, access and competition
Hospitals typically acquire SAPIEN 3 Ultra through bundled contracts that include valves, delivery systems and support, with per-valve prices sitting in a high four-figure to low five-figure US dollar range depending on market and volume. In Europe, national procurement creates additional pressure, with some centres negotiating down list prices significantly.
The valve competes most directly with Medtronic's self-expanding CoreValve/Evolut family and Boston Scientific's LOTUS Edge in certain geographies, each with its own deployment profile and learning curve. For operators familiar with balloon-expandable TAVI, SAPIEN 3 Ultra often feels like a consistent, incremental step rather than a radical break.
Corporate context and shares
Edwards Lifesciences, led by CEO Michael Mussallem, has built its franchise around structural heart therapies, where SAPIEN remains a flagship. The company also develops surgical valves, critical care monitoring and transcatheter mitral and tricuspid solutions that sit alongside Ultra in its portfolio.
Edwards Lifesciences shares (ISIN US28176E1082) trade on the New York Stock Exchange in US dollars, with the SAPIEN franchise frequently cited by analysts as a key driver for long-term revenue and margin trends.
Key facts on SAPIEN 3 Ultra
- Product: SAPIEN 3 Ultra transcatheter heart valve system
- Manufacturer: Edwards Lifesciences Corp.
- Category: New release/launch structural heart device
- Launch: CE mark and initial European launch announced in February 2020, with subsequent roll-out in the US and other regions
- RRP / Price: Typically high four- to low five-figure US dollar range per valve, depending on contract and market
- Availability: Specialist heart centres and cath labs in North America, Europe and selected Asia-Pacific markets; not sold directly to individual consumers
- Target group: Patients with severe, symptomatic aortic stenosis who are at elevated risk for surgical valve replacement
- Highlight / USP: Lower-profile balloon-expandable TAVI system with an enhanced outer skirt designed to further reduce paravalvular leak compared with SAPIEN 3
This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.
